Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases.

Ha EV, Rogers DF.

Pharmacology. 2016;97(1-2):84-100. doi: 10.1159/000442794. Epub 2015 Dec 17. Review.

2.

Therapeutic options for hydrating airway mucus in cystic fibrosis.

Tildy BE, Rogers DF.

Pharmacology. 2015;95(3-4):117-32. doi: 10.1159/000377638. Epub 2015 Mar 19. Review.

3.

Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells.

Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G.

Respir Res. 2012 Oct 31;13:98. doi: 10.1186/1465-9921-13-98.

4.

New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.

Lai H, Rogers DF.

J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):219-31. doi: 10.1089/jamp.2009.0802. Review.

PMID:
20695774
5.

Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.

Lai HY, Rogers DF.

Curr Opin Allergy Clin Immunol. 2010 Feb;10(1):67-76. doi: 10.1097/ACI.0b013e328334643a. Review.

PMID:
19907312
6.

Novel targets and drugs in inflammatory lung disease.

Donnelly LE, Rogers DF.

Curr Opin Pharmacol. 2008 Jun;8(3):219-21. doi: 10.1016/j.coph.2008.04.007. Epub 2008 May 22. No abstract available.

PMID:
18502177
7.

Proteomic analysis of polymeric salivary mucins: no evidence for MUC19 in human saliva.

Rousseau K, Kirkham S, Johnson L, Fitzpatrick B, Howard M, Adams EJ, Rogers DF, Knight D, Clegg P, Thornton DJ.

Biochem J. 2008 Aug 1;413(3):545-52. doi: 10.1042/BJ20080260.

PMID:
18426393
8.

Phytoceuticals: the new 'physic garden' for asthma and chronic obstructive pulmonary disease.

Grandhi S, Donnelly LE, Rogers DF.

Expert Rev Respir Med. 2007 Oct;1(2):227-46. doi: 10.1586/17476348.1.2.227.

PMID:
20477187
9.

Mucoactive agents for airway mucus hypersecretory diseases.

Rogers DF.

Respir Care. 2007 Sep;52(9):1176-93; discussion 1193-7. Review.

10.

Physiology of airway mucus secretion and pathophysiology of hypersecretion.

Rogers DF.

Respir Care. 2007 Sep;52(9):1134-46; discussion 1146-9. Review.

11.

The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation?

Gwilt CR, Donnelly LE, Rogers DF.

Pharmacol Ther. 2007 Aug;115(2):208-22. Epub 2007 May 25. Review.

PMID:
17597218
12.
13.

Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation.

Holder E, Griesenbach U, Li S, Huang L, Rogers DF, Jeffery PK, Geddes DM, Alton EW.

Gene Ther. 2006 Dec;13(23):1628-38. Epub 2006 Jun 22.

PMID:
16791284
14.

Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Foster KA, Adams EJ, Durose L, Cruttwell CJ, Marks E, Shone CC, Chaddock JA, Cox CL, Heaton C, Sutton JM, Wayne J, Alexander FC, Rogers DF.

Neurotox Res. 2006 Apr;9(2-3):101-7.

PMID:
16785105
15.

Treatment of airway mucus hypersecretion.

Rogers DF, Barnes PJ.

Ann Med. 2006;38(2):116-25. Review.

PMID:
16581697
16.

Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma.

Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE.

Respir Med. 2005 Jun;99(6):703-10. Epub 2004 Dec 13.

17.

Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options.

Rogers DF.

Pulm Pharmacol Ther. 2005;18(1):1-8. Review.

PMID:
15607121
18.

Airway mucus hypersecretion in asthma: an undervalued pathology?

Rogers DF.

Curr Opin Pharmacol. 2004 Jun;4(3):241-50. Review.

PMID:
15140415
19.

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD.

Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, Barnes PJ, Donnelly LE.

Thorax. 2003 Nov;58(11):942-6.

20.

Therapy for chronic obstructive pulmonary disease in the 21st century.

Donnelly LE, Rogers DF.

Drugs. 2003;63(19):1973-98. Review.

PMID:
12962514
21.

Pulmonary mucus: Pediatric perspective.

Rogers DF.

Pediatr Pulmonol. 2003 Sep;36(3):178-88. Review.

PMID:
12910578
22.

Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy.

Rogers DF.

Curr Allergy Asthma Rep. 2003 May;3(3):238-48. Review.

PMID:
12662474
23.

The airway goblet cell.

Rogers DF.

Int J Biochem Cell Biol. 2003 Jan;35(1):1-6. Review.

PMID:
12467641
24.

Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease.

Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, Barnes PJ.

Am J Respir Crit Care Med. 2003 Jan 1;167(1):24-31. Epub 2002 Sep 17.

PMID:
12406856
25.

Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory?

Rogers DF.

Clin Exp Allergy. 2002 Aug;32(8):1124-7. Review. No abstract available.

PMID:
12190646
26.

Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease.

Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ.

Am J Respir Crit Care Med. 2002 May 15;165(10):1371-6.

PMID:
12016098
27.

Pharmacological regulation of the neuronal control of airway mucus secretion.

Rogers DF.

Curr Opin Pharmacol. 2002 Jun;2(3):249-55. Review.

PMID:
12020465
28.

Comparison of the effects of salmeterol and formoterol in patients with severe asthma.

Nightingale JA, Rogers DF, Barnes PJ.

Chest. 2002 May;121(5):1401-6.

PMID:
12006420
29.

Mucoactive drugs for asthma and COPD: any place in therapy?

Rogers DF.

Expert Opin Investig Drugs. 2002 Jan;11(1):15-35. Review.

PMID:
11772318
30.

Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease.

Culpitt SV, Rogers DF.

Expert Opin Pharmacother. 2000 Jul;1(5):1007-20. Review.

PMID:
11249492
31.

Motor control of airway goblet cells and glands.

Rogers DF.

Respir Physiol. 2001 Mar;125(1-2):129-44. Review.

PMID:
11240157
32.

Mucus hypersecretion in chronic obstructive pulmonary disease.

Rogers DF.

Novartis Found Symp. 2001;234:65-77; discussion 77-83. Review.

PMID:
11199104
33.

Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets.

Khan S, Liu YC, Khawaja AM, Manzini S, Rogers DF.

Br J Pharmacol. 2001 Jan;132(1):189-96.

34.

Measurement of airway mucin gene expression.

Pritchard K, Smith AK, Rogers DF.

Methods Mol Med. 2001;56:285-94. doi: 10.1385/1-59259-151-5:285.

PMID:
21336908
35.

Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy.

Rogers DF.

Monaldi Arch Chest Dis. 2000 Aug;55(4):324-32. Review.

PMID:
11057087
36.

Airway inflammation after controlled exposure to diesel exhaust particulates.

Nightingale JA, Maggs R, Cullinan P, Donnelly LE, Rogers DF, Kinnersley R, Chung KF, Barnes PJ, Ashmore M, Newman-Taylor A.

Am J Respir Crit Care Med. 2000 Jul;162(1):161-6.

PMID:
10903236
37.

No effect of inhaled budesonide on the response to inhaled ozone in normal subjects.

Nightingale JA, Rogers DF, Chung KF, Barnes PJ.

Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):479-86.

PMID:
10673189
38.
39.
41.
42.

COPD: new developments and therapeutic opportunities.

Rogers DF, Barnes PJ.

Trends Pharmacol Sci. 1999 Sep;20(9):352-4. No abstract available.

PMID:
10515795
43.

Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma.

Nightingale JA, Rogers DF, Barnes PJ.

Am J Respir Crit Care Med. 1999 Jun;159(6):1786-90.

PMID:
10351919
44.

Effects and interactions of opioids on plasma exudation induced by cigarette smoke in guinea pig bronchi.

Lei YH, Rogers DF.

Am J Physiol. 1999 Mar;276(3):L391-7. doi: 10.1152/ajplung.1999.276.3.L391.

PMID:
10070101
46.

Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects.

Nightingale JA, Rogers DF, Hart LA, Kharitonov SA, Chung KF, Barnes PJ.

Thorax. 1998 Jul;53(7):563-71.

47.

New ideas on the pathophysiology and treatment of lung disease.

Rogers DF, Laurent GJ.

Thorax. 1998 Mar;53(3):200-3. Review.

48.

Asthma therapy for the 21st century.

Rogers DF, Giembycz MA.

Trends Pharmacol Sci. 1998 May;19(5):160-4. Review. No abstract available.

PMID:
9652186
50.

Effect of repeated sputum induction on cell counts in normal volunteers.

Nightingale JA, Rogers DF, Barnes PJ.

Thorax. 1998 Feb;53(2):87-90.

Supplemental Content

Loading ...
Support Center